|View printer-friendly version|
ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting
ASLAN003 is an orally active, potent inhibitor of Dihydroorotate Dehydrogenase (DHODH) that has the potential to be first-in-class in acute myeloid leukaemia (AML). In previous clinical studies, ASLAN003 has demonstrated potent inhibition of DHODH (up to two orders of magnitude stronger than first generation DHODH inhibitors), lack of toxicities associated with first generation inhibitors and other novel AML therapies, and the potential to induce differentiation in blast cells and applicability in a broad range of AML patients.
ASLAN will present preliminary results from an ongoing multicentre, single arm phase 2a dose optimisation study of ASLAN003 in AML patients who are ineligible for standard therapy.
In a second poster, new data from a preclinical study evaluating the effects of ASLAN003 on cell growth, differentiation, apoptosis, and gene expression changes in AML cell lines and primary bone marrow cells from patients with AML will be presented.
Details of the accepted abstracts are listed below and are now available online on the ASH conference website: http://www.hematology.org/Annual-Meeting/Abstracts/.
Poster Number: 2676
Poster Number: 4047
Media and IR contacts
Forward looking statements
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Source: ASLAN Pharmaceuticals Limited